中国肿瘤生物治疗杂志2025，Vol.32Issue(11)：1169-1174,6.DOI:10.3872/j.issn.1007-385x.2025.11.009
白蛋白结合型紫杉醇联合PD-1抑制剂在一线治疗失败的骨与软组织肉瘤中的疗效与安全性分析
Efficacy and safety of albumin-binding paclitaxel combined with PD-1 inhibitors in the treatment of bone and soft tissue sarcoma after first-line therapy failure
摘要
Abstract
Objective:To investigate the efficacy and safety of albumin-binding paclitaxel combined with PD-1 inhibitor in the treatment of bone and soft tissue sarcomas after first-line chemotherapy failure.Methods:This retrospective study analyzed patients with advanced bone and soft tissue sarcomas who failed first-line chemotherapy and were treated at the Department of Orthopedic Oncology of Beijing Jishuitan Hospital between August 2017 and August 2020.Patients received combined treatment with albumin-binding paclitaxel(125-140 mg/m2 on days 1 and 8)and anti-PD-1 therapy(sintilimab or toripalimab,every 21 days).Efficacy was evaluated every two treatment cycles according to the RECIST 1.1 criteria and adverse reactions were assessed using the NCI-CTC5.0 criteria.Results:A total of 20 patients who completed between 1 to 8 cycles of treatment with a median of 3 cycles were included in the study.All patients were evaluable for responses:4 patients(20%)achieved complete remission;no partial remissions were observed;9 patients(45%)had stable disease,and 7 patients(35%)had disease progression.The overall response rate(ORR)was 20%,and the disease control rate(DCR)was 65%.The median progression-free survival(PFS)was 3.0 months.The main adverse reactions during treatment included Grade 2 leukopenia(40%),Grade 1-2 neurotoxicity(20%),and Grade 2 hypothyroidism(10.0%).Conclusion:The combination therapy of albumin-binding paclitaxel and PD-1 inhibitor offers a potential treatment option for patients with advanced bone and soft tissue sarcomas who have failed first-line chemotherapy.The adverse reactions are manageable,and this regimen merits prospective studies with larger samples to further verify its efficacy.关键词
一线化疗失败/白蛋白结合型紫杉醇/PD-1抑制剂/骨与软组织肉瘤Key words
first-line treatment failure/albumin-bound paclitaxel/PD-1 inhibitor/bone and soft tissue sarcoma分类
医药卫生引用本文复制引用
黄真,刘巍峰,李远,徐海荣,张清,郝林,牛晓辉..白蛋白结合型紫杉醇联合PD-1抑制剂在一线治疗失败的骨与软组织肉瘤中的疗效与安全性分析[J].中国肿瘤生物治疗杂志,2025,32(11):1169-1174,6.基金项目
北京积水潭医院"学科新星"(No.XKXX2018013) （No.XKXX2018013）
